Physician profile
William E Cogburn
NPI 1063438430
$3,693.25
in general payments reported to CMS, 2019-2025
30 companies · $67.47 in 2025
The $67.47 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $578 · 2021: $379 · 2022: $844 · 2023: $600 · 2024: $618 · 2025: $67.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $395.68 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $370.57 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $354.92 | 2020-2023 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $325.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $282.88 | 2021-2024 | Qulipta, Vraylar, Ubrelvy |
| Pfizer INC. | $187.89 | 2019-2024 | |
| Astellas Pharma US INC | $162.97 | 2019-2024 | Veozah, Myrbetriq |
| Galderma Laboratories, L.P. | $143.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.05 | 2019-2023 | Stiolto Respimat |
| Kowa Pharmaceuticals America, INC. | $127.11 | 2019-2022 | |
| Glaxosmithkline, LLC. | $116.28 | 2020-2023 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $110.98 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.04 | 2019-2024 | Xifaxan |
| Amarin Pharma, INC. | $94.71 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $91.53 | 2019-2024 | Airsupra, Farxiga |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $89.74 | 2019-2021 | |
| Boston Scientific Corporation | $81.28 | 2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $72.50 | 2019-2022 | |
| Radius Health, INC. | $72.22 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $57.04 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $56.13 | 2021 | |
| Sumitomo Pharma America, INC. | $53.71 | 2024 | Gemtesa |
| Biohaven Pharmaceutical Holding Company Ltd. | $40.35 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $29.65 | 2020-2022 | |
| Genentech USA, INC. | $28.38 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.11 | 2022 | |
| Allergan, INC. | $21.34 | 2020 | |
| Sanofi Pasteur INC. | $18.57 | 2019 | |
| Philips North America LLC | $17.44 | 2024 | (Ck7) Extended Holter |
| Ibsa Pharma INC. | $15.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cogburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.